Pacira BioSciences, Inc. PCRX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $7.03M— | —— | $41.96M— | —— | ||
| $91.02M+15.5% | $78.79M+4.2% | $75.57M-17.4% | $91.5M+221% | ||
| $57.5M+12.4% | $51.17M+6.8% | $47.9M-0.4% | $48.09M+13.8% | ||
| —— | $20.62M+32.1% | $15.62M+297% | -$7.95M— | ||
| $3.02M-6.3% | $3.22M-14.0% | $3.75M-14.8% | $4.4M+59.8% | ||
| $10.74M+38.6% | $7.75M+8.2% | $7.16M+244% | $2.08M-80.1% | ||
| —— | $20.93M+152% | $8.29M+433% | -$2.49M-156% | ||
| -$5.6M— | —— | —— | —— | ||
| $6.85M— | —— | —— | —— | ||
| —— | -$61K— | —— | —— | ||
| —— | $2.71M— | —— | —— | ||
| —— | —— | —— | -$29.48M— | ||
| $151.99M-19.7% | $189.39M+22.5% | $154.65M+6.5% | $145.27M+15.6% | ||
| $15.33M+44.2% | $10.64M-29.8% | $15.16M-49.6% | $30.08M-34.4% | ||
| —— | $0— | $0— | $0-100% | ||
| $141.04M-44.1% | $252.21M+83.3% | $137.61M-64.5% | $387.69M-36.6% | ||
| $273.81M+52.5% | $179.57M-24.3% | $237.07M-0.2% | $237.58M-77.8% | ||
| $99.48M+219% | -$83.28M-202% | $81.88M— | —— | ||
| $148.33M+493% | $25M— | —— | $0— | ||
| —— | —— | $0— | —— | ||
| —— | $0-100% | $1.94M-92.0% | $24.39M+2.3% | ||
| $5.62M+1,044% | $491K+363% | $106K— | $0— | ||
| -$369.63M— | —— | -$183.47M+54.3% | -$401.53M-205% | ||
| -$77K— | —— | $0— | —— | ||
| -$129.19M-204% | $124.56M— | —— | -$481.44M-199% | ||
| $15.24M-1.2% | $15.42M-44.2% | $27.64M-17.0% | $33.3M+376% | ||
| —— | $11.02M+152% | $4.37M-41.0% | $7.4M+130% | ||
| —— | $7.42M+62.2% | $4.58M— | —— | ||
| —— | $3.22M-14.0% | $3.75M— | —— | ||
| —— | —— | —— | -$29.48M— | ||
| $0+100% | -$2.17M— | $0— | $0— | ||
| $6.85M-52.5% | $14.43M+167% | -$21.61M— | —— | ||
| —— | -$61K— | —— | —— | ||
| —— | $236K— | —— | $285K-89.3% | ||
| $141.04M-44.1% | $252.21M+83.3% | $137.61M-64.5% | $387.69M-36.6% | ||
| $273.81M+52.5% | $179.57M-24.3% | $237.07M-0.2% | $237.58M-77.8% | ||
| —— | —— | —— | $78.13M— | ||
| —— | —— | —— | —— | ||
| $0— | $0-100% | $149.55M— | —— | ||
| $1.79M— | $0— | $0— | —— | ||
| —— | —— | —— | —— | ||
| $136.66M-23.5% | $178.75M+28.1% | $139.49M+21.1% | $115.2M+44.3% | ||
| $136.66M-23.5% | $178.75M+28.1% | $139.49M+21.1% | $115.2M+44.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pacira BioSciences, Inc. generate?
- Pacira BioSciences, Inc. (PCRX) generated $142.2M in operating cash flow over the trailing twelve months.
- What is Pacira BioSciences, Inc.'s free cash flow?
- After $9.5M of capital expenditures, Pacira BioSciences, Inc.'s free cash flow was $132.7M over the trailing twelve months, down 16.8% year over year.
- Where does Pacira BioSciences, Inc.'s cash flow data come from?
- Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
